Literature DB >> 3385723

Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes.

R McCague1, G Leclercq, V C Jordan.   

Abstract

Substituted 8,9-diphenyl-6,7-dihydro-5H-benzocycloheptenes 6-8, which are ring-fused analogues of (Z)-trans-4-hydroxytamoxifen, (E)-cis-tamoxifen, and (E)-cis-4-hydroxytamoxifen, were synthesized from 7-methoxy-1-benzosuberone. The hydroxy compounds 6 and 8 were individually prepared via a common synthetic intermediate from which either the perfluoro-p-tolyl or the methyl ether functions could be cleaved specifically. Compounds were assayed for binding affinity to estrogen receptors in cytosol and in MCF-7 whole cells and for growth inhibition of MCF-7 cells in vitro and rat uteri in vivo. The endocrinological properties of the cyclic analogues 5-7 paralleled those of the corresponding derivatives of tamoxifen although in the MCF-7 assay 6 was slightly less effective than 4-hydroxytamoxifen at 10(-6) and 10(-7) M. The compound 8 analogues to cis-4-hydroxytamoxifen antagonized the growth stimulation by estradiol of MCF-7 cell or rat uterus growth, and it is therefore an antiestrogen, but its potency was somewhat less, both as an antiestrogen and an estrogen, than reported for cis-4-hydroxytamoxifen attributable to modification of the biochemical properties of the latter by isomerization to the more potent trans isomer. Curiously, in the absence of estradiol, compound 8 stimulated MCF-7 cell growth at low concentration (10(-8) M) but inhibited growth at higher concentration. In contrast, compound 7, which lacked the hydroxy function, was a full estrogen in the rat uterine growth assay. These compounds should be ideal for further structure-activity studies of triarylethylene-based antiestrogens without complications caused by isomerization.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3385723     DOI: 10.1021/jm00402a005

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Synthesis and in vitro receptor binding studies of fluorotamoxifen analogues.

Authors:  D J Yang; S Wallace; W Tansey; K C Wright; L R Kuang; R S Tilbury; I Diego; J L Lim; A M Emran; E E Kim
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

2.  Selective synthesis of either enantiomer of an anti-breast cancer agent via a common enantioenriched intermediate.

Authors:  Aaron George Johnson; Marissa M Tranquilli; Michael R Harris; Elizabeth R Jarvo
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

3.  The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.

Authors:  C K Osborne; M Jarman; R McCague; E B Coronado; S G Hilsenbeck; A E Wakeling
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.

Authors:  P Saladores; T Mürdter; D Eccles; B Chowbay; N K Zgheib; S Winter; B Ganchev; B Eccles; S Gerty; A Tfayli; J S L Lim; Y S Yap; R C H Ng; N S Wong; R Dent; M Z Habbal; E Schaeffeler; M Eichelbaum; W Schroth; M Schwab; H Brauch
Journal:  Pharmacogenomics J       Date:  2014-08-05       Impact factor: 3.550

5.  Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.

Authors:  Philipp Y Maximov; Daphne J Fernandes; Russell E McDaniel; Cynthia B Myers; Ramona F Curpan; V Craig Jordan
Journal:  J Med Chem       Date:  2014-05-22       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.